(Q54652791)

2 June 2018

title

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. (English)

1 reference

2 June 2018

author

Hojjat Ahmadzadehfar

6

1 reference

2 June 2018

James Nagarajah

8

1 reference

2 June 2018

author name string

Amir Sabet

1

1 reference

2 June 2018

Khaled Ezziddin

2

1 reference

2 June 2018

Ulrich-Frank Pape

3

1 reference

2 June 2018

Karl Reichman

4

1 reference

2 June 2018

Torjan Haslerud

5

1 reference

2 June 2018

Hans-Jürgen Biersack

7

1 reference

2 June 2018

Samer Ezziddin

9

1 reference

2 June 2018

publication date

6 November 2013

1 reference

2 June 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

2 June 2018

volume

41

1 reference

2 June 2018

issue

3

1 reference

2 June 2018

page(s)

505-510

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s00259-013-2601-x

exact match

0 references

cites work

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

End-stage renal disease after treatment with 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

MDRD equations for estimation of GFR in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2601-X

New advances in peptide receptor radionuclide therapy.

21 January 2018

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

12 December 2020

Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats

1 reference

12 December 2020

The nonuniformity of antibody distribution in the kidney and its influence on dosimetry

1 reference

12 December 2020

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging

1 reference

12 December 2020

Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE

1 reference

12 December 2020

Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection

1 reference

12 December 2020

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

12 December 2020

Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake

1 reference

12 December 2020

10.1007/S00259-013-2601-X

Identifiers

DOI

1 reference

2 June 2018

release_uhlydkpvebc6rkzhhgcgqoj7oa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uhlydkpvebc6rkzhhgcgqoj7oa

24 November 2022

mapped directly with Wikidata item

PubMed ID

24196919

1 reference

2 June 2018